Nuvation Bio
NUVB
129 hedge funds and large institutions have $228M invested in Nuvation Bio in 2023 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 46 increasing their positions, 37 reducing their positions, and 13 closing their positions.
24% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 37
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
2% more funds holding
Funds holding: 126 → 129 (+3)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.93% less ownership
Funds ownership: 64.05% → 63.12% (-0.93%)
15% less capital invested
Capital invested by funds: $267M → $228M (-$39.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.5M |
| 2 |
AIC
AWM Investment Company
New York
|
+$1.82M |
| 3 |
Axa
Paris,
France
|
+$753K |
| 4 |
NYLIM
New York Life Investment Management
New York
|
+$577K |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$572K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
-$9.23M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.53M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$4.98M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$1.32M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$1.01M |
NUVB Hedge Fund Activity: Q1 2023 in Review
129 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Nuvation Bio (NUVB) for Q1 2023, worth a combined $228M — down 15% from $267M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new NUVB positions and 13 closed out — a net gain of 3 holders — while 46 added to existing stakes and 37 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $12.5M. The largest seller was Baupost Group, exiting entirely with an estimated $9.23M sold.
- 129 institutional investors held Nuvation Bio (NUVB) as of Q1 2023, up from 126 in Q4 2022.
- Funds reported $228M of Nuvation Bio stock for Q1 2023, down 15% quarter-over-quarter.
- 16 funds opened new Nuvation Bio positions in Q1 2023 and 13 closed out, a net change of +3 holders.
- The largest Nuvation Bio buyer in Q1 2023 was Fidelity Investments, an estimated $12.5M added.
- The largest Nuvation Bio seller in Q1 2023 was Baupost Group, an estimated $9.23M sold.
Based on aggregated 13F filings for Q1 2023.